Fantastic #ASCO2019 for $BPMC: BLU-667 works in pts previously treated with LOXO-292, those with RET-fusion+ pancreatic cancer, and targets brain mets! Granted BREAKTHROUGH THERAPY designation by the FDA ....SO proud to have worked on this molecule! #RET #BLU667 #NSCLC

What happens to tumor markers when highly selective medicines are given to genomically defined cancer patients. #targetedtherapy #NSCLC #MTC #BLU667 #kinaseinhibitors $BPMC #lungcancer

#AACR18 BLU667 against ret tumors

BPMC's BLU-667 is well tolerated and shrinks tumors in over 80% of patients in a Ph1 trial! $LOXO goes up, $BPMC down?! #BLU667 #RET #AACR2018

Our full programme is now available to view on our website: retatcrick.wixsite.com/retatcrick. #multipleEndocrineNeoplasia2 #MedullaryThyroidCancer #NSCLC #HirschsprungsDisease #TracerX #BLU667 #oncology #Endocrinology #Gastroenterology

Alectinib (450 mg BUD) in 25 Japanese RET TKI naive, ORR of 4%, PFS 3.4 mo and OS 19 mo. Efficacy independent of RET fusion partner. Lower RR related to dose? Why do you should use unselective RET TKI when selective RET TKI (BLU667 and LOXO292) reported RR ~65% and icRR #WCLC2019

Capuzzo

Encouraging data with Selpercatinib and BLU667 in RET fused NSCLC

#lcsm #alcc2020

We have shown the target engagement and inhibition of downstream signaling(AKT, MTOR, MAPK, AKT and STAT pathways) that was comparable to the current approved inhibitors selpercatinib(LOXO292) and pralsetinib(BLU667) and superior to the multi-kinase RET inhibitor vandetanib. 6/14

Two RET-specific inhibitors are FDA-approved: selpercatinib(LOXO292) and pralsetinib(BLU667); ORR 60-89%. Unfortunately, tumors can overcome the inhibition and progress. Expanding the armamentarium of RET inhibitors can strengthen the clinical control of RET-driven cancers. 3/14

Capmatinib FDA-approved for MET ex14skipping mutation+ NSCLC

About 1/3 of NSCLC patients have indication 4 targeted tx by now,& the pie chart is enlarging day by day

RET may be next, w\ more BLU667 & LOXO292 data presented in #ASCO20 , & several KRAS-i trials ongoing

OncoAlert

Also very proud of being one of the investigators in #ARROW praseltinib (BLU667) in RET+ #LCSM FDA approval likely to come soon bringing more options to patients #ASCO20 @oncoalert @sylvestercancer @totalhealthcon

Great slide by Robert C. Doebele, MD, PhD to compare data available on selpercatinib (LOXO292) and pralsetinib (BLU667). Both drugs quite active, slightly different toxicity profiles. Interesting to me the higher drug discontinuation rate for pralsetinib. #WCLC19 #LCSM #OncoAlert

#ret #loxo292 #blu667 #LCSM #ASCO18

Few days after I arrived in IEO, we enrolled the 1st patient in #ARROW

I’ll never forget his first CT scan. I remember mailing it to G Curigliano MD PhD, w/ object: “tumor has disappeared!!!”

Since that day, it is in front of my desk - reminder of the beauty of clinical research

#BLU667

Astonishing results of selpercatinib for RET+ NSCLC now out on NEJM

➡️ORR 64% in chemo-pretreated pts, but 85% ‼️ in 1L!
➡️mDoR 17 mos‼️
➡️intracranial ORR 91%‼️

Together w/ BLU667 (pralsetinb) these data set a revolution for RET+NSCLC

OncoAlert #lcsm
nejm.org/doi/full/10.10…

Very eager to have access to clinical trials including tak788 for exon 20 egfr and blu-667 for RET Takeda Blueprint Medicines AP-HP Hôpital Cochin-Port-Royal AP-HP #ASC019 #LCSM #tak788 #blu667

Martin Forster @UCLH / @UCLCancer talks about next generation #RETinhibitor #BLU667 from @blueprintmeds in #lungcancer and #medullarythryoidcancer / #MTC at the novel #RETatCRICK meeting, 10 June, London: retatcrick.wixsite.com/retatcrick #NSCLC #endocrinology #oncology #EndocrineCancer

Gainor: BLU667 ARROW RET fusion update. RP2D 490mg OD. 66% RET-KIF5B. N91 prior platinum. 18% prior TKI. Constipation, Netripnia, Htension. 7% discont. ORR 60% prior plat. 5/7 treatment naive responded. Responses seen in CNS and different fusions #ASCO19 #LCSM

$BPMC weakness in pre-market. Focus on LOXO selpercatinib PFS/DOR vs estimated BLU667 from ASCO2019 (per RayJay note below)

#BLU -667: El inhibidor selectivo de RET ha demostrado respuestas duraderas en pacientes con #CáncerDePulmón con fusión positiva RET en el estudio de fase I de ARROW. Aquí se discute la importancia de estas alteraciones en el #NSCLC y su prevalencia: 🔎bit.ly/37u1FVm